Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 751-764

  Hoi, P M ^a   Visintin, C ^b   Okuyama, M ^b   Gardiner, S M ^c   Kaup, S S ^a   Bennett, T ^c   Baker, D ^d   Selwood, D L ^b   Hiley, C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AM 251; Cannabinoid receptors; Endothelium; GPR55; Haemodynamics; O 1918; Rat mesenteric artery; Rimonabant; Vasodilator; VSN16

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 3 (5 DIMETHYLCARBAMOYL PENT 1 ENYL) N (2 HYDROXY 1 METHYL ETHYL)BENZAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BENZAMIDE DERIVATIVE; CALCIUM CHANNEL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; NITRIC OXIDE; O 1918; POTASSIUM CHANNEL; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE MEASUREMENT; CEREBELLUM; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SYNTHESIS; HEMODYNAMICS; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; VASCULAR RESISTANCE; VASCULARIZATION; VASODILATATION;

ANIMALS; APAMIN; BENZAMIDES; CANNABINOIDS; CEREBELLUM; CHARYBDOTOXIN; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; INDOMETHACIN; MALE; MESENTERIC ARTERIES; MOLECULAR STRUCTURE; NG-NITROARGININE METHYL ESTER; PERTUSSIS TOXIN; PIPERIDINES; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RESORCINOLS; TRITIUM; TRPV CATION CHANNELS; VASCULAR RESISTANCE; VASODILATION;

EID: 35649010952     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707470     Document Type: Article

References (47)

1. Baker D, Pryce G, Davies WL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27: 1-4.
2. Brown AJ, Wise A (2001). GlaxoSmithKline. Identification of modulators of GPR55 activity Patent WO01/86305.
3. Chataigneau T, Félétou M, Thollon C, Villeneuve N, Vilaine JP, Duhault J et al. (1998). Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol 123: 968-974.
4. Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520: 539-550.
5. 1) receptor expression is associated with mesenteric resistance vessels but not thoracic aorta in the rat. Br J Pharmacol 125: 95P.
6. Drmota T, Greasley P, Groblewski T (2004). AstraZeneca. Screening assays for cannabinoid-ligand type modulators of GPR55 Patent WO2004/074844.
7. Duncan M, Kendall DA, Ralevic V (2004). Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. J Pharmacol Exp Ther 311: 411-419.
8. Gardiner SM, March JE, Kemp PA, Bennett T (2002). Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 135: 1889-1996.
9. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61: PL 191-PL 197.
10. Griffin G, Wray EJ, Martin BR, Abood ME (1999). Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. Br J Pharmacol 128: 684-688.
11. 2+ influx. Br J Pharmacol 139: 585-597.
12. Ho WS, Hiley CR (2003b). Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138: 1320-1332.
13. Ho WS, Hiley CR (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 56: 869-875.
14. Hoi PM (2007). Cannabinoid receptor pharmacology in the rat small mesenteric artery. PhD thesis; University of Cambridge, Cambridge, UK.
15. Hoi PM, Hiley CR (2006). Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147: 560-568.
16. Hopper AT, Witiak DT, Ziemniak J (1998). Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid. J Med Chem 41: 420-427.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
18. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400-8405.
19. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
20. Johns DG, Behm DJ, Walker D, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 binds atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 152: 825-831 (this issue).
21. Kadota I, Shibuya L, Lutete LM, Yamamtoto Y (1999). Palladium/benzoic acid catalyzed hydroamination of alkynes. J Org Chem 64: 4570-4571.
22. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769-776.
23. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
24. Okuyama M, Selwood D, Visintin C, Baker D, Pryce G (2005). University College London. Modulators of cannabinoid receptors. Patent WO2005/080316.
25. O'Sullivan SE, Kendall DA, Randall MD (2004). Characterisation of the vasorelaxant properties of the novel endocannabinoid Narachidonoyl-dopamine (NADA). Br J Pharmacol 141: 803-812.
26. 9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145: 514-526.
27. Offertáler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
28. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
29. Petitet F, Donlan M, Michel A (2006). GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67: 252-253.
30. Poblete IM, Orliac ML, Briones R, Adler-Graschinsky E, Huidobro-Toro JP (2005). Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. J Physiol 568: 539-551.
31. Ralevic V, Kendall DA (2001). Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 418: 117-125.
32. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, Hogestatt ED (2000). Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol 130: 1483-1488.
33. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C et al. (1995). Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947.
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
35. Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK (1997). Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chem 40: 3617-3625.
36. Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
37. Sjögren S, Ryberg E, Lindblom A, Larsson N, Hermansson N-O, Åstrand A et al. (2005). A new receptor for cannabinoid ligands. International Cannabinoid Research Society XVth Symposium on the Cannabinoids: 106. (www.cannabinoidsociety.org).
38. Smith PF (2004). Medicinal cannabis extracts for the treatment of multiple sclerosis. Curr Opin Investig Drugs 5: 727-730.
39. Szallasi A, Blumberg PM (1999). Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159-212.
40. Wagner JA, Varga K, Járai Z, Kunos G (1999). Mesenteric vasodilation mediated by endothelial anandamide receptor. Hypertension 33: 429-434.
41. White R, Hiley CR (1997a). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122: 1573-1584.
42. White R, Hiley CR (1997b). Endothelium and cannabinoid receptor involvement in levcromakalim vasorelaxation. Eur J Pharmacol 339: 157-160.
43. White R, Hiley CR (1998a). The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J Pharmacol 125: 533-541.
44. White R, Hiley CR (1998b). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125: 689-696.
45. Williamson EM, Evans FJ (2000). Cannabinoids in clinical practice. Drugs 60: 1303-1314.
46. 2 cannabinoid receptor-independent mechanism. J Neurosci 22: 4720-4727.
47. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, DiMarzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.